Blue Jet Healthcare Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Blue Jet Healthcare Limited (NSE:BLUEJET) just released its latest third-quarter results and things are looking bullish. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 18% higher than the analysts had forecast, at ₹3.2b, while EPS were ₹5.71 beating analyst models by 46%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Blue Jet Healthcare

Taking into account the latest results, the current consensus from Blue Jet Healthcare's four analysts is for revenues of ₹12.7b in 2026. This would reflect a huge 45% increase on its revenue over the past 12 months. Per-share earnings are expected to leap 46% to ₹19.78. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹11.9b and earnings per share (EPS) of ₹16.21 in 2026. So it seems there's been a definite increase in optimism about Blue Jet Healthcare's future following the latest results, with a considerable lift to the earnings per share forecasts in particular.

With these upgrades, we're not surprised to see that the analysts have lifted their price target 35% to ₹707per share. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Blue Jet Healthcare at ₹770 per share, while the most bearish prices it at ₹640. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Blue Jet Healthcare's growth to accelerate, with the forecast 35% annualised growth to the end of 2026 ranking favourably alongside historical growth of 8.3% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Blue Jet Healthcare to grow faster than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Blue Jet Healthcare's earnings potential next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Blue Jet Healthcare analysts - going out to 2027, and you can see them free on our platform here.

We also provide an overview of the Blue Jet Healthcare Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.